|Mr. Michael Amoroso||President, CEO & Director||979.04k||N/A||1978|
|Mr. John Alexander Kelly R.Ph.||CFO & Principal Accounting Officer||623.58k||N/A||1967|
|Mr. Dario Scimeca||General Counsel & Secretary||576.43k||N/A||1976|
|Dr. Derek Jantz Ph.D.||Co-Founder & Chief Science Advisor||597.38k||N/A||1976|
|Dr. Jefferson J. Smith Ph.D.||Co-Founder & Chief Research Officer||N/A||N/A||1973|
|Mei Burris||Director of Investor Relations & Finance||N/A||N/A||N/A|
|Mr. Bruce Stevens||Vice President of Quality & Compliance||N/A||N/A||N/A|
|Maurissa Messier||Senior Director of Corporate Communications||N/A||N/A||N/A|
|Ms. Juli Blanche||Chief People Officer||N/A||N/A||N/A|
|Mr. Garrett Gincley||Head of Manufacturing||N/A||N/A||N/A|
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences, Inc.’s ISS governance QualityScore as of 28 November 2023 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 8.